RxDoctor Payments Data

Emanuel Kouroupos, MD

Gastroenterology · Astoria, NYNPI 1043281280

Payments from drug & device makers

$4,589in general payments, 2019–2025

Across 151 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • AstraZeneca$955
  • Phathom Pharmaceuticals, Inc.$438
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
  • Madrigal Pharmaceuticals$222
  • Exact Sciences$207
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,589 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$151,500
Medicare patients
431
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$33,233
JanuviaSitagliptin Phosphate18$28,009
XareltoRivaroxaban23$14,105
CreonLipase/Protease/Amylase11$8,494
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates131$6,979
Mesalamine DrMesalamine13$5,534
Entecavir13$5,011
Mesalamine17$4,421
Omeprazole323$2,154
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,096
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,966
SynthroidLevothyroxine Sodium32$1,941
Famotidine206$1,896
Sucralfate25$1,732
Levothyroxine Sodium122$1,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$33,23328 claims
Johnson & JohnsonXarelto$150$14,10523 claims
AbbVieCreon, Synthroid$18$10,43543 claims
Braintree Laboratories, Inc.Sutab$41$2,09613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →